Showing 7861-7870 of 8465 results for "".
- Novan Announces Robert A. Ingram as Chairmanhttps://practicaldermatology.com/news/novan-announces-robert-a-ingram-as-chairman/2458716/Novan, Inc. named Robert A. Ingram as Chairman of the Board of Directors of Novan. In addition, Robert Keegan has been appointed to the Board of Directors. The company also announced that it received $32.8 million of net proceeds in a private Mezzanine B financing in December 2015 from it
- Antiperspirant, Deodorant Use Disrupts Microbiomehttps://practicaldermatology.com/news/antiperspirant-deodorant-use-disrupts-microbiome/2458718/Wearing antiperspirant or deodorant may influence the type and quantity of bacterial life found in the armpit's microbiome, new research suggests. "Using antiperspirant and deodorant completely rearranges the microbial ecosystem of your skin -- what's
- Take That, Zika! New Wearable Device Protects Against Mosquitoes that Transmit Zikahttps://practicaldermatology.com/news/take-that-zika-new-wearable-device-protects-against-mosquitoes-that-transmit-zika/2458722/OFF!® Clip-On™ repellent device may help keep Zika-carrying mosquitoes at bay, according to an article in the Journal of Medical Entomol
- Meet the Neocutis' Family's Newest Add: Micro-Firm Neck and Décolleté Rejuvenating Complexhttps://practicaldermatology.com/news/meet-the-neocutis-familys-newest-add-micro-firm-neck-and-dcollet-rejuvenating-complex/2458723/Neocutis’ Micro-Firm Neck and Décolleté Rejuvenating Complex is slated to hit physician’s offices in March 2016. The cream, which will be the newest addition to the Neocutis family of anti-aging products, targets the delicate
- BioPharmX Corporation Appoints Craig A. Barbarosh to its Board of Directorshttps://practicaldermatology.com/news/biopharmx-corporation-appoints-craig-a-barbarosh-to-its-board-of-directors/2458734/BioPharmX Corporation appointed Craig A. Barbarosh to its board of directors. He will serve as an independent board member on the audit and compensation committees and will chair the nominating and corporate governance committee. Mr. Barbarosh is a member of the board of directors o
- Bristol-Myers Squibb's Opdivo + Yervoy Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Statushttps://practicaldermatology.com/news/bristol-myers-squibbs-opdivo-yervoy-regimen-receives-expanded-fda-approval-in-unresectable-or-metastatic-melanoma-across-braf-status/2458732/The FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma. This indication is
- Surgical Specialties Corporation Acquires FSSB Chirurgische Nadein GMBHhttps://practicaldermatology.com/news/surgical-specialties-corporation-acquires-fssb-chirurgische-nadein-gmbh/2458735/Surgical Specialties Corporation has acquired all shares of FSSB Chirurgische Nadein GMBH (FSSB) and affiliated entities. Terms were not disclosed. The acquisition will be immediately accretive to both Surgical Specialties' sales and adjusted EBITDA. FSSB was founded in 1995 by c
- New Web Tool May Curb Indoor Tanning Use Among Coedshttps://practicaldermatology.com/news/new-web-tool-may-curb-indoor-tanning-use-among-coeds/2458737/A web-based intervention that taps into indoor tanning users’ perceptions about the value of tanning may help curb tanning bed use among young females, suggests research out of Rutgers Cancer Institute of New Jersey in New Brunswick. Research has shown that some indoor tanners do so
- Review Article Shines Spotlight on Neurocutaneous Disordershttps://practicaldermatology.com/news/review-article-shines-spotlight-on-neurocutaneous-disorders/2458739/There are at least 60 genetic neurocutaneous disorders that involve the skin, central nervous system, according to a review article in the Current Neurology and Neuroscience Reports. For example, neurofibrom
- Data: EpiDuo Forte Shows Benefit in Severe Inflammatory Acnehttps://practicaldermatology.com/news/data-epiduo-forte-shows-benefit-in-severe-inflammatory-acne/2458743/New data suggest that Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5% from Galderma, recently approved for the treatment of moderate to severe acne vulgaris, may have benefit for the topical treatment of severe inflammatory acne. Data published for the in the Dece